“The acceptance of the rucaparib NDA submission represents an important milestone for rucaparib, and for Clovis,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “There is tremendous ...

After skin cancer, prostate cancer is the most common form of cancer in American men, according to The American Cancer Society. About 191,930 new cases of prostate cancer will be diagnosed this year, ...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the ...

Nine patients treated to date with 177Lu-FAP-2286 up to 5.5 GBq/dose No serious adverse events, treatment discontinuations, deaths or dose-limiting toxicity events related to 177Lu-FAP-2286 observed ...

Anna Sussman Thank you, Chris. Good morning, everyone. And welcome to the Clovis Oncology fourth quarter and full year 2021 conference call. Thank you for joining us. You have likely seen this morning ...

What: After announcing that the response rate on its lead cancer drug is less than previously reported, shares in Clovis Oncology cratered 68.5% in November. So what: Clovis Oncology had already filed ...

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that Dale Hooks has been named Senior Vice President and Chief Commercial Officer. Mr. Hooks succeeds Steve ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

BOULDER, Colo. (AP) -- Biotech drugmaker Clovis Oncology Inc. said Friday it plans to sell $75 million in stock. The company said it expects to raise $69.9 million from the offering after expenses and ...

PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Between November ...

Shares in biotechnology companies can make breathtaking moves higher and lower on whims and whispers and June was no exception. Following a rollicking ride higher last year and dramatic sell-off in ...